



RANBAXY

19 December 2008, Tokyo and Gurgaon

Ranbaxy Reconstitutes Board of Directors following Strategic Alliance with Japan's Daiichi Sankyo

Ranbaxy CEO and Managing Director Malvinder Mohan Singh Takes Additional Role as Chairman of the Board

December 19, 2008, Tokyo and Gurgaon – Daiichi Sankyo Company Limited (TSE: 4568.JP) ("Daiichi Sankyo") and Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") today announced the reconstitution of Ranbaxy's Board of Directors.

The reconstitution was approved by Ranbaxy's Board of Directors at a meeting held today at the Company's headquarters in Gurgaon, India. The composition of the new Board reflects the new ownership structure at Ranbaxy, India's largest pharmaceuticals company, following Daiichi Sankyo's strategic investment completed in November 2008. Daiichi Sankyo now holds 63.92% of the equity share capital of Ranbaxy.

The reconstituted Board is dedicated to realizing the benefits of the global partnership between Daiichi Sankyo and Ranbaxy in the creation and provision of innovative pharmaceutical products that enrich the quality of human life.

Mr. Malvinder Mohan Singh, CEO & MD, additionally assumes the role of Chairman of the Board of Directors. Ranbaxy will maintain its status as a publicly listed company and will continue to operate as an independent and autonomous entity. Underlining Daiichi Sankyo's strong commitment to the partnership, Ranbaxy's Board now includes Mr. Takashi Shoda, President & CEO of Daiichi Sankyo.

Mr. Shoda, commented:

"These appointments signify both companies' absolute commitment to driving success for this strategic alliance. I am confident that with the leadership team we now have in place, Ranbaxy will swiftly make a significant contribution to the Daiichi Sankyo Group. I believe this unique hybrid business model allows both companies to fully realize their strengths and will become the standard for growth in the pharmaceutical industry of the future."

Mr. Singh, said:

"I would like to acknowledge the substantial contribution made by the erstwhile Board in guiding Ranbaxy to its current position of leadership. It gives me great pleasure to welcome the new Board that brings with it continuity, enormous experience, global competencies and a cross-functional perspective. Our transformational alliance with Daiichi Sankyo marks a paradigm shift in the landscape of the pharmaceutical industry. This definitive step emphasizes our vision of bringing high quality, affordable medicines within easy reach of all."

Ranbaxy's Board of Directors now comprises:

<u>Title</u>	<u>Name</u>	<u>Current Position</u>
Chairman, CEO, Managing Director	Malvinder Mohan Singh	Chief Executive Officer & Managing Director Ranbaxy Laboratories Limited
COO	Atul Sobti	Chief Operating Officer Ranbaxy Laboratories Limited
Director	Takashi Shoda	President & Chief Executive Officer Daiichi Sankyo Co., Ltd.
Director	Tsutomu Une	Member of the Board, Senior Executive Officer Daiichi Sankyo Co., Ltd.
Director	Sunil Godhwani	Chief Executive Officer & Managing Director Religare Enterprises Limited
Director	Anthony H. Wild	General Partner

		BOWS Pharmaceuticals AG
Director	Rajesh V. Shah	Co-Chairman & Managing Director Mukand Ltd.
Director	Akihiro Watanabe	Representative Director GCA Savvian Group
Director	Balinder Singh Dhillon	Advocate

Mr. Malvinder Mohan Singh has also become a member of the senior global management team of Daiichi Sankyo.

Subsequent to the reconstitution of Ranbaxy's Board, several Committees of the Board including the Audit, Remuneration and Shareholder/Investors Committees have also been reconstituted.

About Daiichi Sankyo Company, Limited

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections.

For more information, visit: www.daiichisankyo.com

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

For more information, visit: www.ranbaxy.com

For further information, please contact:

Daiichi Sankyo Co., Ltd.
3-5-1, Nihonbashi Honcho,
Chuo-ku, Tokyo 103-8426, Japan

Mr. Toshiaki Sai, (General Manager, Corporate Communications)
Mr. Masaya Tamae (Director, Public Relations)
Mr. Shigemichi Kondo (Director, Investor Relations)
Tel: +81-3-6225-1126

Ranbaxy Laboratories Limited
Plot 90, Sector 32, Gurgaon
Haryana 122001, India

Ramesh L. Adige
President - Corporate Affairs and
Global Corporate Communications
Tel: +91-124-4135000
email: ramesh.adige@ranbaxy.com

Raghu Kochar
Director-Corporate Communications
email: raghu.kochar@ranbaxy.com
Tel: +91-124-4135141
Mobile: 9811617256

Krishnan Ramalingam
Sr. Manager-Corporate Communications
email: krishnan.ramalingam@ranbaxy.com
Tel: +91-124-4135143
Mobile: 9810042540